• Keynote 695 Clinical Trial
  • Advancing OncoSec
OncoSec logo OncoSec mobile logo
  • ABOUT
    • About
    • Join the Team
    • Management Team
  • PIPELINE
  • TECHNOLOGY
    • Technology
    • TAVO
    • Combination Approach
    • Publications
  • PARTNERING
  • PATIENTS
    • Patients
    • Resources
    • Expanded Access
  • INVESTORS
  • MEDIA
  • CONTACT

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO™, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer

May 23, 2019 8:30am EDT

OncoSec Medical Incorporated Prices $11,000,000 Public Offering

May 22, 2019 8:45am EDT

OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer

May 22, 2019 8:30am EDT

OncoSec Medical Incorporated Announces Proposed Public Offering

May 21, 2019 4:01pm EDT

OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries

May 21, 2019 8:30am EDT

OncoSec Announces 1-for-10 Reverse Stock Split

May 20, 2019 12:45pm EDT

OncoSec to Present at ThinkEquity Conference 2019

Apr 29, 2019 8:00am EDT

OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors

Apr 24, 2019 8:00am EDT

OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO™, Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer

Apr 23, 2019 8:00am EDT

OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO™ in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center

Apr 17, 2019 8:00am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...37
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    footer logo

    Sign Up for our mailing list to stay current on all of our exciting new research and developments.

    Get Email Alerts

    Links

    • ABOUT
    • PIPELINE
    • TECHNOLOGY
    • PARTNERING
    • PATIENTS
    • INVESTORS
    • MEDIA & EVENTS
    • CONTACT
    • KEYNOTE 695 CLINICAL TRIAL

    Contact

    New Jersey Headquarters
    24 N. Main St
    Pennington, NJ 08534

    R&D Laboratories
    3565 General Atomics Court #100
    San Diego, CA 92121

    p | 855.622.6732

    f | 858.430.3832

    Investors@OncoSec.com

    © 2019 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E. OncoSec’s investigational products have not been approved or cleared by the FDA.